RCMT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Given the user's beginner investment knowledge, long-term preference, and available capital, RCMT is not a strong buy at this moment. While the company shows solid financial growth and positive analyst sentiment, the pre-market price decline, insider selling, and lack of recent positive news or trading signals suggest waiting for a more favorable entry point.
The technical indicators show a mixed picture. The MACD is positive but contracting, RSI is neutral at 68.468, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support and resistance levels are Pivot: 29.454, R1: 31.655, S1: 27.254, R2: 33.014, S2: 25.895. However, the pre-market price has declined by -1.97%, indicating potential short-term weakness.
Strong financial performance in Q4 2025, with revenue up 12.43% YoY, net income up 112.91% YoY, and EPS up 118.92% YoY.
Positive analyst sentiment with a raised price target to $36 and a Buy rating.
Insiders are selling, with a 338.63% increase in selling activity over the last month.
No recent news or significant hedge fund activity.
Pre-market price decline of -1.97%.
In Q4 2025, RCMT demonstrated strong financial growth: Revenue increased by 12.43% YoY to $86,476,000, net income surged by 112.91% YoY to $6,104,000, and EPS grew by 118.92% YoY to 0.81. However, gross margin slightly declined by -0.29% YoY to 27.43%.
Benchmark raised the price target from $32 to $36 and maintained a Buy rating, citing stronger operating leverage and potential upside in Engineering Services despite cautious views on Life Sciences in FY26.
